glp 1 agonists with cardiovascular benefit agonist risks GLP-1 receptor agonist-based therapies and risk: a review of Benefits and drawbacks of GLP-1

After 68 weeks, they lost almost 15% of their body weight

The inhibitory effect of glucagon-like peptide-1 (GLP-1) 736 amide on gastric acid secretion in humans depends on an intact vagal innervation

This requires carefully designed clinical trials that account for commercial dynamics, as well as pre-launch disease education to prime market understanding regarding where new therapies fit in the treatment paradigm

UNICEF highlights that over 340 million children and adolescents aged 519 are overweight or obese, while chronic disease burden continues rising globally, encouraging development of improved long-acting and patient-friendly drug formulations to enhance treatment adherence and long-term outcomes

GLUTag, InR1-G9, or RIN1056A glucagon-producing tumors all exhibited marked enlargement of the small bowel

Role of Prohormone Convertases in the Tissue-Specific Processing of Proglucagon